Going off all the new posters today, I'd suggest that the low is...

Going off all the new posters today, I'd suggest that the low is in and the stop loss hunters have filled their desired positions.

SP is a gift at the moment. I suspect the bow will be tied and cu6 will be sold for $20-$30/share within 6-12 months. The average premium paid by BP is 100% to last closing price, however for more sort after assets this can be as high as 200%. I.e. if the SP is $8, we could expect to wake up one morning with an offer of $24 ($5B USD market cap).

Before the down rampers lose their mind over a $5B USD acquisition price..

"GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by 2030"

https://www.globaldata.com/media/pharma/radiopharmaceuticals-prostate-cancer-go-nuclear-6-3-billion-sales-2030-forecasts-globaldata/#:~:text=17%20Sep%2C%202024%20Radiopharmaceuticals%20for,sales%20by%202030%2C%20forecasts%20GlobalData&text=Radioligand%20therapies%20(RLTs)%20have%20received,companies%20in%20treating%20prostate%20cancer.

Remember Alan is a former investment banker with a significant holding so there's no doubt in my mind that he'll be able to negotiate a great outcome for shareholders.